ISSN: 1859 - 2872
Initial results of stereotatic body radiotherapy for hepatocellular carcinoma patients with portal vein thrombosis at 108 Military Central Hospital
Main Article Content
Keywords
Stereotactic body radiotherapy, portal vein thrombosis, hepatocellular carcinoma
Abstract
Objective: To evaluate the initial result and toxicity of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) patients with portal vein thrombosis. Subject and method: A prospective study on 30 HCC patients with portal vein thrombosis were treated by SBRT, follow-up between July, 2018 to April, 2021. Evaluation criteria were ojective response rate (ORR), overall survival (OS), toxicity and cause of death. Result: Thrombosis location: Vp4 + Vp3 (53.3%). Mean radiation dose was 35.7 ± 3.1Gy/3 - 5 fraction. The ORR after 1 month, 3 months were 80%, 73.3%, respectively. The median OS was 14.5 months. The OS rate after 6 month, 1-year were 96.7%, 63.3%. Most of toxicities were grade 1-2 including fatigue, nausea, abdominal pain. Conclusion: SBRT is a safe and effective treatment option for PVT in HCC patients with minor toxicity.
Article Details
References
1. Bray F, Ferlay J, Seorjomataram I et al (2018) Golbal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality wordwide for 36 cancers in 185 countries. A cancer Journal for Clinician 68(6): 394-424.
2. Minagawa M, Makuuchi M (2006) Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 47: 7561-7567.
3. Llovet JM, Bustamante J, Castells A et al (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology, 29(1): 62-67.
4. Cheng AL, Guan Z, Chen Z, et al (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial. European Journal of Cancer 48(10): 1452-1465.
5. Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised Phase 3 non-inferiority trial. Lancet 391(10126): 1163-1173.
6. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers version 5.2020.
7. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC) (2015) 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 16: 465-522.
8. Bộ Y tế (2020) Quyết định số 3129/QĐ-BYT về việc ban hành tài liệu chuyên môn Hướng dẫn chẩn đoán và điều trị ung thư biểu mô tế bào gan.
9. Tublin ME, Dodd GD, Richard LB (1997) Benign and malignant portal vein thrombosis: Differentiation by CT characteristics. AJR: 168.
10. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19(3): 329-338.
11. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer, Inst 100: 698-711.
12. Choi HS, Kang KM, Jeong BK et al (2020) Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease. Asia Pac J Clin Oncol 17(3): 209-215. https://doi.org/ 10.1111/ ajco.13361.
13. Shui Y, Yu W, Ren X et al (2018) Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiation Oncology 13: 188.
14. Jeong BK (2018) Stereotactic-body radiotherapy for portal vein tumor thrombosis in hepatocellular carcinoma patients. Journal of Clinical Oncology 36(4): 442-442.
15. Que J, Wu HC, Lin CH et al (2020) Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis. Medicine 99: 13. DOI: 10.1097/MD. 0000000000019660.
2. Minagawa M, Makuuchi M (2006) Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 47: 7561-7567.
3. Llovet JM, Bustamante J, Castells A et al (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology, 29(1): 62-67.
4. Cheng AL, Guan Z, Chen Z, et al (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial. European Journal of Cancer 48(10): 1452-1465.
5. Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised Phase 3 non-inferiority trial. Lancet 391(10126): 1163-1173.
6. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers version 5.2020.
7. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC) (2015) 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 16: 465-522.
8. Bộ Y tế (2020) Quyết định số 3129/QĐ-BYT về việc ban hành tài liệu chuyên môn Hướng dẫn chẩn đoán và điều trị ung thư biểu mô tế bào gan.
9. Tublin ME, Dodd GD, Richard LB (1997) Benign and malignant portal vein thrombosis: Differentiation by CT characteristics. AJR: 168.
10. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19(3): 329-338.
11. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer, Inst 100: 698-711.
12. Choi HS, Kang KM, Jeong BK et al (2020) Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease. Asia Pac J Clin Oncol 17(3): 209-215. https://doi.org/ 10.1111/ ajco.13361.
13. Shui Y, Yu W, Ren X et al (2018) Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiation Oncology 13: 188.
14. Jeong BK (2018) Stereotactic-body radiotherapy for portal vein tumor thrombosis in hepatocellular carcinoma patients. Journal of Clinical Oncology 36(4): 442-442.
15. Que J, Wu HC, Lin CH et al (2020) Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis. Medicine 99: 13. DOI: 10.1097/MD. 0000000000019660.
Article Sidebar
Published
Jun 2, 2021
Section
Articles
How to Cite
NgaD. T., TuấnN. A., ChâuN. Đình, BiểuB. Q., KỳT. D., ThịnhN. T., & BàngM. H. (2021). Initial results of stereotatic body radiotherapy for hepatocellular carcinoma patients with portal vein thrombosis at 108 Military Central Hospital. Tạp Chí Y Dược lâm sàng 108, 17(DB). https://doi.org/10.52389/ydls.v17iDB.1280